Stocktoria
Cytek Biosciences, Inc. CTKB
Nasdaq · XNAS · stock · Laboratory Analytical Instruments · website · IPO 2021-07-23
Cytek Biosciences, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 51.8% | 55.4% | 56.7% | 61.6% | 61.9% |
| Operating margin | -20.0% | -10.2% | -14.4% | -1.1% | 7.2% |
| Net margin | -33.0% | -3.0% | -6.3% | 1.5% | 2.4% |
| FCF margin | -4.4% | 10.9% | 0.3% | -13.4% | 0.2% |
| Return on assets | -14.4% | -1.2% | -2.5% | 0.5% | 0.7% |
| Return on equity | -19.5% | -1.5% | -3.1% | 0.6% | 0.7% |
| Current ratio | 5.04 | 5.86 | 6.97 | 9.26 | 13.01 |
| Revenue growth | 0.5% | 3.9% | 17.7% | 28.2% | 37.8% |
Source: SEC EDGAR filings · CIK 0001831915 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.